Innogenetics NV
This article was originally published in The Gray Sheet
Executive Summary
Firm's North American subsidiary Innogenetics, Inc. acquires Avant Immunotherapeutics' TRAx diagnostic product line for an undisclosed amount in cash and royalty payments, the firms announce Aug. 25. The deal gives Innogenetics worldwide rights to "sell, market and manufacture" the diagnostics "as well as the patent and trademark portfolio." The TRAx CD4 enzyme-linked immunoassay was launched in the U.S. in 1995 following 510(k) clearance and is indicated to enumerate CD4 T cells via monoclonal antibodies to measure specific T lymphocytes in blood samples
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.